bupropion: the legal and safety record

The guilty plea

In July 2012, GlaxoSmithKline pleaded guilty to a federal criminal information that included introducing misbranded Wellbutrin into interstate commerce — promotion for uses the FDA had not approved — as part of a $3 billion criminal and civil resolution, the largest health-care-fraud settlement in U.S. history at the time [1]. Precision the headlines usually skip: the $3 billion covered conduct across several drugs (Paxil, Wellbutrin, Avandia, and civil claims on others), so no Wellbutrin-only dollar figure exists. What is specific to bupropion is the criminal count itself — one of the few times an antidepressant’s marketing produced a guilty plea rather than a civil settlement. Paroxetine’s half of that plea lives on its own page.

The generic the FDA un-approved

Budeprion XL 300 mg — a generic copy of Wellbutrin XL — had been approved on testing of the 150 mg strength, extrapolated upward. Patients who switched from the brand reported, for years, that the copy hit faster and faded — lost effect, new side effects — and for years the answer was that generics are identical by definition. In 2012 the FDA’s own sponsored study found the 300 mg product did not release bupropion at the same rate and extent as the brand; distribution stopped in September 2012, and the agency formally withdrew approval by Federal Register notice in March 2013 [2]. It is the clearest documented case in this library of patient reports being right before the paperwork was — worth keeping in mind wherever “anecdotes aren’t data” gets used to end a conversation rather than start a study.

The warning that was removed

Zyban — bupropion packaged for smoking cessation — carried boxed-warning language about serious neuropsychiatric events for seven years. The FDA required the manufacturers to test the question properly: EAGLES randomized roughly 8,000 smokers, with and without psychiatric history, across varenicline, bupropion, nicotine patch and placebo [3]. Clinically significant neuropsychiatric events occurred at similar rates on treatment and placebo, and in December 2016 the FDA removed the serious-neuropsychiatric-events language from the boxed warning [3][4]. This series spends most of its pages on warnings that arrived late; here is the mechanism running the other way — a warning retired by evidence. Both motions are the system working; a library that only showed you one would be selling something.

What remains boxed today is the class-wide antidepressant warning, verbatim from the current label: “Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials.” [4]

What is not in the record

• No mass-tort settlement. Unlike several drugs in this series, bupropion has no large injury-litigation resolution on the public record.
• No Class I recall — twenty-two enforcement records, all Class II or III [5]. The Budeprion action was an approval withdrawal, not a safety recall.

Common questions

Was there a lawsuit about Wellbutrin marketing?

A criminal case, resolved by guilty plea. In July 2012 GlaxoSmithKline pleaded guilty to a three-count federal information — two counts of introducing misbranded drugs (Paxil and Wellbutrin) into interstate commerce and one count of failing to report safety data on a diabetes drug — as part of a $3 billion criminal and civil resolution, the largest health-care-fraud settlement in U.S. history at the time. The Wellbutrin count concerned promotion for uses the FDA had not approved. The $3 billion covered conduct across several drugs; no public breakdown assigns a Wellbutrin-only figure.

Was a generic version of Wellbutrin really taken off the market?

Yes — and by the FDA's own study. Budeprion XL 300 mg (Impax/Teva) had been approved based on testing of the 150 mg strength, extrapolated upward. Patients who switched from the brand complained for years about lost effect and new side effects. In 2012 an FDA-sponsored bioequivalence study found the 300 mg product did not release bupropion at the same rate and extent as Wellbutrin XL 300; distribution stopped that September, and the FDA formally withdrew approval in a March 2013 Federal Register notice. Other manufacturers' 300 mg generics were subsequently re-tested, and one more was withdrawn.

Does bupropion have a black box warning?

Yes — the class-wide antidepressant suicidality warning, quoted verbatim on this page. But bupropion is also the rare drug that has had boxed-warning language REMOVED: in December 2016, after the ~8,000-patient EAGLES trial the FDA had required, the agency removed the serious-neuropsychiatric-events language from the boxed warning of Zyban (bupropion for smoking cessation). Clinically significant neuropsychiatric events occurred at similar rates on treatment and placebo.

Has bupropion been recalled?

No Class I recall appears in the openFDA enforcement database — twenty-two records, six Class II and sixteen Class III, none Class I. The Budeprion withdrawal above was an approval withdrawal for bioequivalence failure, a different mechanism from a safety recall.

Considering bupropion itself? The bupropion page has the approval basis, prescription volumes, and label warnings, sourced the same way.

Sources

Last verified 2026-09-01. Corrections change this date.